Applied Biosystems TaqPath Covid-19 high throughput Combo Kit is designed for use with Thermo Fisher’s Automated Amplitude platform
Thermo Fisher rolls out new Covid-19 diagnostic assay. (Credit: Thermo Fisher Scientific Inc.)
Thermo Fisher Scientific has launched its CE-IVD-Marked Applied Biosystems TaqPath Covid-19 HT Kit, which can be used with the Automated Amplitude platform.
Automated Amplitude platform is a molecular diagnostic system that combines Thermo Fisher’s extraction and real-time PCR instruments with liquid handling products from Tecan Group.
The high-throughput diagnostic assay is said to help laboratories test up to 8,000 Covid-19 samples per day, with reduced staffing requirements, reagents and consumables.
Thermo Fisher Scientific genetic sciences business president Mark Smedley said: “Accurate and reliable testing that can scale is essential in addressing the spread of any disease, especially Covid-19.
“The Amplitude platform embodies our goal of empowering public health and clinical lab professionals to generate accurate results at higher volumes and use them to make informed health care decisions that lead to the management of a pandemic that is still raging around the world.”
The high-throughput version of Thermo Fisher’s TaqPath Covid-19 CE-IVD RT-PCR Kit, compatible with the Amplitude platform, has been granted CE-IVD Mark in March 2020.
The high throughput diagnostic assay has also received Health Canada Interim Order Authorisation on 21 January 2021.
Thermo Fisher said that a large provincial authority in Canada has awarded a contract for its Amplitude systems to fight the pandemic.
The company is capable of producing more than 20 million tests per week and is working with laboratories, governments, academic institutions and others to ensure a reliable supply of tests and materials.